{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study was terminated based on the strategic re-evaluation of the clinical development of surufatinib in the United States and Europe with no safety concerns."},"pointOfContact":{"email":"nicolam@hutch-med.com","organization":"HUTCHMED Limited","phone":"+44 7738 881999","title":"Nicky Murray"}}